Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1Disease 1DLBCL 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

Bevacizumab 5Everolimus 4Sirolimus 2Lapatinib 2HDAC-42 2vistusertib 1temsirolimus 1neratinib 1icotinib 1emvododstat 1brolucizumab 1brigatinib 1aflibercept 1Vascular Endothelial Growth Factor A 1Valproic Acid 1Sunitinib 1Magnetic Resonance Imaging 1Immunoglobulin G 1Endostatins 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Axitinib 1Aspirin 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibromatosis 2 × vistusertib × Clear all
NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡